拜耳选择宏盟集团作为其消费者健康部门的全球媒体、制作和创意代理合作伙伴-动脉网

Bayer selects Interpublic as global media, production and creative agency partner for Consumer Health Division

拜耳等信源发布 2025-09-30 16:37



可切换为仅中文







September

九月

2025

10:31 AM

上午10点31分

Europe/Amsterdam

欧洲/阿姆斯特丹

Bayer selects Interpublic as global media, production and creative agency partner for Consumer Health Division

拜耳选择宏盟集团作为其消费者健康部门的全球媒体、制作和创意代理合作伙伴

New era in building trusted brands

构建值得信赖品牌的新时代

Basel, Switzerland September 29, 2025

瑞士巴塞尔，2025年9月29日

– The Consumer Health division of Bayer has selected Interpublic Group (NYSE: IPG) as the global agency partner for all creative, production and media, responsible for marketing activities for some of the most trusted and well-known brands in self-care.

拜耳消费者健康部门选择了宏盟集团（纽约证券交易所代码：IPG）作为其全球代理合作伙伴，负责所有创意、制作和媒体工作，为一些最受信赖和知名的自我护理品牌开展营销活动。

The selection of an integrated agency across brands and regions represents a new era in how Bayer intends to grow consumer love and trust in iconic brands like Aspirin, Bepanthen, Claritin, Canesten and more. The shift intends to capitalize on the acceleration of GenAI tools and capabilities to better engage with consumers at the local level..

跨越品牌和地区的综合代理机构的选择，代表了拜耳希望在如阿司匹林、贝帕森、开瑞坦、凯妮汀等标志性品牌上赢得消费者喜爱与信任的新时代。这一转变旨在利用生成式人工智能工具和能力的加速发展，更好地在本地层面吸引消费者。

“Our new agency model addresses two competing forces in today’s marketing landscape - the need for more connection and individuality alongside greater efficiency and automation,’ said David Evendon-Challis from the Consumer Health Division of Bayer. “IPG understands how data, AI and creative must converge in this new era and came forward with a strong offering that brings together world class capabilities, innovative technologies, and creativity.

“我们的新代理模式解决了当今营销领域中的两种竞争力量——对更多连接和个性的需求，以及对更高效率和自动化的追求，”拜耳消费者健康部门的David Evendon-Challis表示。“IPG 深知在这个新时代中，数据、人工智能和创意必须如何融合，并提出了一个强大的方案，将世界级的能力、创新技术和创造力结合在一起。”

We are excited for them to join with us on this journey and by the opportunity of what is possible when their planned combination with Omnicom is complete.”.

我们很高兴他们能与我们一同踏上这段旅程，并期待他们的计划与奥姆尼康集团合并完成后所带来的可能性。"

“We are honored and energized by Bayer’s decision,” said Philippe Krakowsky, Chief Executive Officer, Interpublic Group. “In today’s fragmented and fast-moving marketing environment, clients are looking for partners who can integrate creativity and media with data and technology in ways that are seamless and connected.

“我们为拜耳的决定感到荣幸并充满活力，”宏盟集团首席执行官菲利普·克拉科夫斯基表示。“在当今碎片化且快速变化的营销环境中，客户正在寻找能够以无缝且互联的方式将创意、媒体与数据和技术整合在一起的合作伙伴。”

What makes this opportunity exciting is the scale and ambition of Bayer’s portfolio — trusted brands with enormous reach and impact. By bringing the full IPG ecosystem together, we will deliver bold ideas, smarter media, and technology-enabled production that accelerate growth, deepen consumer trust, and drive results across markets.

这个机会令人兴奋的地方在于拜耳产品组合的规模和雄心——这些值得信赖的品牌拥有巨大的影响力和覆盖范围。通过整合整个IPG生态系统，我们将提供大胆的创意、更智能的媒体以及技术支持的制作，从而加速增长、加深消费者信任并在各个市场推动成果。

We look forward to tapping additional talent and capabilities on Bayer’s behalf once we join forces with Omnicom.”.

我们期待着一旦与宏盟集团联手，能够为拜耳挖掘更多的人才和能力。

The new integrated agency approach is designed to deliver world-class media buying power across the world to enhance Bayer’s ability to connect with consumers with content that is more personalized and responsive to their needs. It is also built on a flexible operating model to scale brand building activities with global consistency while maintaining local relevance..

新的整合机构方法旨在为拜耳提供世界级的全球媒体购买能力，以增强拜耳通过更加个性化和响应消费者需求的内容与消费者建立联系的能力。该方法还基于一个灵活的运营模式，在保持全球一致性的同时扩大品牌建设活动，并保留本地相关性。

After a transition and handover period, Bayer expects to go live with the new agency structure on January 1.

经过一段过渡和交接期，拜耳预计新的代理架构将于1月1日正式启动。

About Bayer

关于拜耳

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population.

拜耳是一家在医疗保健和营养等生命科学领域具有核心竞争力的全球性企业。秉承“人人健康，无饥饿”的使命，公司的产品和服务旨在帮助人类和地球繁荣发展，支持应对不断增长和老龄化的全球人口所带来的重大挑战。

Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros.

拜耳致力于通过其业务推动可持续发展并产生积极影响。同时，集团旨在通过创新和增长提高盈利能力并创造价值。拜耳品牌在全球范围内代表着信任、可靠性和质量。在2024财年，该集团拥有约93,000名员工，销售额达466亿欧元。

R&D expenses amounted to 6.2 billion euros. For more information, go to .

研发费用总计达62亿欧元。欲了解更多信息，请访问。

www.bayer.com

。

Forward-Looking Statements

前瞻性声明

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

本发布可能包含基于拜耳管理层当前假设和预测的前瞻性声明。各种已知和未知的风险、不确定性和其他因素可能导致公司的实际未来结果、财务状况、发展或业绩与这里给出的估计存在重大差异。

These factors include those discussed in Bayer’s public reports which are available on the Bayer website at .

这些因素包括拜耳公开报告中讨论的因素，这些报告可在拜耳网站上查阅。

www.bayer.com

. The company assumes no liability whatsoever to update these forward-looking statements or to conform

公司不承担更新这些前瞻性声明或使其符合的任何责任 whatsoever

them to future events or developments.

将它们应用于未来的事件或发展。

Contact for media inquiries:

媒体查询请联系：

Ex-U.S.

美国以外